The relative expression ratio of MAX to MYCN is a key factor in disease progression and clinical prognosis: a higher MAX/MYCN ratio can inhibit the oncogenic effects of MYCN and improve neuroblastoma prognosis (Lu et al., 2003). The gene discussed is MYCN; the disease is neuroblastoma.